What is Kodiak Sciences Price-to-Operating-Cash-Flow?
As of today (2024-04-27), Kodiak Sciences's share price is $3.28.
Kodiak Sciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.94. Hence, Kodiak Sciences's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Kodiak Sciences's Price-to-Operating-Cash-Flow or its related term are showing as below:
Kodiak Sciences's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $-0.61.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.94.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -17.30% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -21.30% per year.
During the past 8 years, Kodiak Sciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was -17.30% per year. The lowest was -56.30% per year. And the median was -22.00% per year.
Kodiak Sciences Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Kodiak Sciences's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kodiak Sciences Price-to-Operating-Cash-Flow Chart
|
Kodiak Sciences Annual Data
|
|
Trend |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
- |
- |
- |
- |
- |
|
Kodiak Sciences Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Kodiak Sciences's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Kodiak Sciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kodiak Sciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kodiak Sciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Kodiak Sciences's Price-to-Operating-Cash-Flow falls into.
Kodiak Sciences Price-to-Operating-Cash-Flow Calculation
Kodiak Sciences's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 3.28 | / | -2.942 |
| = | |
Kodiak Sciences's Share Price of today is $3.28.
Kodiak Sciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.94.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Kodiak Sciences (Kodiak Sciences) Business Description
Traded in Other Exchanges
Address
1200 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
Executives
| Jason Ehrlich |
officer: See Remarks |
1200 PAGE MILL ROAD, PALO ALTO CA 94304 |
| John A. Borgeson |
officer: See Remarks |
1200 PAGE MILL ROAD, PALO ALTO CA 94304 |
| Baker Bros. Advisors Lp |
director, 10 percent owner |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| Victor Perlroth |
director, 10 percent owner, officer: Chairman, President and CEO |
1200 PAGE MILL ROAD, PALO ALTO CA 94304 |
| Julian Baker |
director, 10 percent owner |
BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
| Felix Baker |
director, 10 percent owner |
BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
| Baker Brothers Life Sciences Lp |
director, 10 percent owner |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| L.p. 667, |
director, 10 percent owner |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| Baker Bros. Advisors (gp) Llc |
director, 10 percent owner |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| Charles A Bancroft |
director |
BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
| Hong Liang |
officer: See Remarks |
2631 HANOVER STREET, PALO ALTO CA 94304 |
| Richard S Levy |
director |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| Taiyin Yang |
director |
2631 HANOVER STREET, PALO ALTO CA 94304 |
| Robert Profusek |
director |
P.O. BOX 696000, SAN ANTONIO TX 78269-6000 |
| Bassil I Dahiyat |
director |
C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016 |
Kodiak Sciences (Kodiak Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KOD has been successfully added to your